User login
PARIS — Treatment of patients with systemic lupus erythematosus with the monoclonal antibody belimumab permitted reductions in corticosteroids through 3 years of observation, according to a post hoc analysis of a large phase II study.
Treatment options for systemic lupus erythematosus (SLE) are limited, and most of the available options are associated with significant and even debilitating adverse effects. Cortico-steroids, for example, are associated with weight gain, risk of infection, psychosis, and hypertension and so generally are reserved for use during times of disease activity. An agent that could be steroid sparing remains a critical unmet need in the SLE treatment regimen, according to Dr. Daniel J. Wallace of Cedars-Sinai Medical Center, University of California, Los Angeles.
Belimumab targets and inhibits soluble B-lymphocyte stimulator (BLyS), a protein that is overexpressed in SLE.
Following the completion of a double-blind trial, patients were allowed to enroll in an open-label extension trial in which they received 10 mg/kg of belimumab monthly. A total of 296 participants chose to continue in the study and 233 remained enrolled at the time of Dr. Wallace's EULAR presentation.
At baseline, the majority of patients were women whose mean age was 42 years. Mean disease duration was 8.8 years, and most patients had a reduction in disease activity as measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) as modified for the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA).
A total of 69% were on daily prednisone, with a mean dose of 11 mg/day, and 36% were on doses higher than 7.5 mg/day.
At the end of the randomized phase, reductions in average prednisone dose to 7.5 mg/day or lower were seen in 34%, 28%, 31%, and 44% of patients in the placebo, 1-mg/kg, 4-mg/kg, and 10-mg/kg groups, while increases from low-dose prednisone to doses of 7.5 mg/day or higher were needed in 17%, 11%, 10%, and 4%, respectively.
At the end of year 3, when patients from all groups were on the highest dose of active treatment, prednisone reductions were seen in 56%, 45%, 61%, and 62% of patients originally in the placebo, 1-mg/kg, 4-mg/kg, and 10-mg/kg groups, and increases were seen in 8%, 5%, 12%, and 7%, respectively.
Dr. Wallace has declared no conflicts of interest.
Treatment options for lupus are limited, and most are associated with significant adverse effects. DR. WALLACE
PARIS — Treatment of patients with systemic lupus erythematosus with the monoclonal antibody belimumab permitted reductions in corticosteroids through 3 years of observation, according to a post hoc analysis of a large phase II study.
Treatment options for systemic lupus erythematosus (SLE) are limited, and most of the available options are associated with significant and even debilitating adverse effects. Cortico-steroids, for example, are associated with weight gain, risk of infection, psychosis, and hypertension and so generally are reserved for use during times of disease activity. An agent that could be steroid sparing remains a critical unmet need in the SLE treatment regimen, according to Dr. Daniel J. Wallace of Cedars-Sinai Medical Center, University of California, Los Angeles.
Belimumab targets and inhibits soluble B-lymphocyte stimulator (BLyS), a protein that is overexpressed in SLE.
Following the completion of a double-blind trial, patients were allowed to enroll in an open-label extension trial in which they received 10 mg/kg of belimumab monthly. A total of 296 participants chose to continue in the study and 233 remained enrolled at the time of Dr. Wallace's EULAR presentation.
At baseline, the majority of patients were women whose mean age was 42 years. Mean disease duration was 8.8 years, and most patients had a reduction in disease activity as measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) as modified for the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA).
A total of 69% were on daily prednisone, with a mean dose of 11 mg/day, and 36% were on doses higher than 7.5 mg/day.
At the end of the randomized phase, reductions in average prednisone dose to 7.5 mg/day or lower were seen in 34%, 28%, 31%, and 44% of patients in the placebo, 1-mg/kg, 4-mg/kg, and 10-mg/kg groups, while increases from low-dose prednisone to doses of 7.5 mg/day or higher were needed in 17%, 11%, 10%, and 4%, respectively.
At the end of year 3, when patients from all groups were on the highest dose of active treatment, prednisone reductions were seen in 56%, 45%, 61%, and 62% of patients originally in the placebo, 1-mg/kg, 4-mg/kg, and 10-mg/kg groups, and increases were seen in 8%, 5%, 12%, and 7%, respectively.
Dr. Wallace has declared no conflicts of interest.
Treatment options for lupus are limited, and most are associated with significant adverse effects. DR. WALLACE
PARIS — Treatment of patients with systemic lupus erythematosus with the monoclonal antibody belimumab permitted reductions in corticosteroids through 3 years of observation, according to a post hoc analysis of a large phase II study.
Treatment options for systemic lupus erythematosus (SLE) are limited, and most of the available options are associated with significant and even debilitating adverse effects. Cortico-steroids, for example, are associated with weight gain, risk of infection, psychosis, and hypertension and so generally are reserved for use during times of disease activity. An agent that could be steroid sparing remains a critical unmet need in the SLE treatment regimen, according to Dr. Daniel J. Wallace of Cedars-Sinai Medical Center, University of California, Los Angeles.
Belimumab targets and inhibits soluble B-lymphocyte stimulator (BLyS), a protein that is overexpressed in SLE.
Following the completion of a double-blind trial, patients were allowed to enroll in an open-label extension trial in which they received 10 mg/kg of belimumab monthly. A total of 296 participants chose to continue in the study and 233 remained enrolled at the time of Dr. Wallace's EULAR presentation.
At baseline, the majority of patients were women whose mean age was 42 years. Mean disease duration was 8.8 years, and most patients had a reduction in disease activity as measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) as modified for the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA).
A total of 69% were on daily prednisone, with a mean dose of 11 mg/day, and 36% were on doses higher than 7.5 mg/day.
At the end of the randomized phase, reductions in average prednisone dose to 7.5 mg/day or lower were seen in 34%, 28%, 31%, and 44% of patients in the placebo, 1-mg/kg, 4-mg/kg, and 10-mg/kg groups, while increases from low-dose prednisone to doses of 7.5 mg/day or higher were needed in 17%, 11%, 10%, and 4%, respectively.
At the end of year 3, when patients from all groups were on the highest dose of active treatment, prednisone reductions were seen in 56%, 45%, 61%, and 62% of patients originally in the placebo, 1-mg/kg, 4-mg/kg, and 10-mg/kg groups, and increases were seen in 8%, 5%, 12%, and 7%, respectively.
Dr. Wallace has declared no conflicts of interest.
Treatment options for lupus are limited, and most are associated with significant adverse effects. DR. WALLACE